Prophylactic effect of ramosetron and dexamethasone on the occurrence of postoperative vomiting

Effects of dexamethasone and ramosetron (Nasea®) on prevention of postoperative nausea and vomiting in low risk patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006749

Enrollment

177

Registered

2021-11-11

Start date

2022-01-03

Completion date

Unknown

Last updated

2021-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : All experimental groups: 3 groups Control: C group: 0.9% saline 2 mL Experimental group: RD group: ramosetron (Nasea®) 0.3 mg + dexamethasone 5 mg R group: ramosetron (Nasea®

0 = no nausea, 10 = worst nausea imaginable) and classified as mild (1–3), moderate (4–6) or severe (7–10). ? When to evaluate - Within 1 hour after surgery - 1-6 hours after surgery - 6-24 hours afte

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults undergoing planned surgery under general anesthesia with 2 or less risk factors for postoperative nausea and vomiting

Exclusion criteria

Exclusion criteria: 1. Preoperative drug users (narcotic analgesics, antiemetics, steroids) 2. Patients with a history of allergy to dexamethasone and ramosetron (Headache, dyspnea, hot flushes, blood pressure drop, rash) 3. Patients with vestibular dysfunction symptoms 4. contraindication to administration due to the existing approval of the test drug

Design outcomes

Primary

Measure	Time frame
incidence of postoperative nausea and vomiting	—

Secondary

Measure	Time frame
severity of postoperative nausea and vomiting	—

Countries

Korea, Republic of

Contacts

Public Contactbyeongmun hwang

Kangwon National University Hospital

arim14@naver.com+82-33-258-2292

Outcome results